Rapamycin Monotherapy in Patients With Type 1 Diabetes Modifies CD4(+)CD25(+)FOXP3(+) Regulatory T-Cells

OBJECTIVE—Rapamycin is an immunosuppressive drug currently used to prevent graft rejection in humans, which is considered permissive for tolerance induction. Rapamycin allows expansion of both murine and human naturally occurring CD4(+)CD25(+)FOXP3(+) T regulatory cells (nTregs), which are pivotal f...

Descripción completa

Detalles Bibliográficos
Autores principales: Monti, Paolo, Scirpoli, Miriam, Maffi, Paola, Piemonti, Lorenzo, Secchi, Antonio, Bonifacio, Ezio, Roncarolo, Maria-Grazia, Battaglia, Manuela
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518485/
https://www.ncbi.nlm.nih.gov/pubmed/18559659
http://dx.doi.org/10.2337/db08-0138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518485/
https://www.ncbi.nlm.nih.gov/pubmed/18559659
http://dx.doi.org/10.2337/db08-0138

Ejemplares similares